MX2020005360A - Compuestos y regimen de dosificacion para usarse en la prevencion o tratamiento de enfermedades inflamatorias cronicas y/o autoinmunes. - Google Patents
Compuestos y regimen de dosificacion para usarse en la prevencion o tratamiento de enfermedades inflamatorias cronicas y/o autoinmunes.Info
- Publication number
- MX2020005360A MX2020005360A MX2020005360A MX2020005360A MX2020005360A MX 2020005360 A MX2020005360 A MX 2020005360A MX 2020005360 A MX2020005360 A MX 2020005360A MX 2020005360 A MX2020005360 A MX 2020005360A MX 2020005360 A MX2020005360 A MX 2020005360A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- prevention
- chronic inflammatory
- dosage regimen
- autoimmune diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a un 2-(ácido{3-fluoro-3'-metoxi- [1,1'-bifenil]-4-il}carbamoil) ciclopent-1-eno-1-carboxílico), de acuerdo con la fórmula (I),(ver formula I), y un nuevo régimen de dosificación, así como sus usos en el tratamiento de enfermedades inflamatorias crónica y/o autoinmunes. Dicho compuesto de fórmula (I) inhibe la dihidroorotato deshidrogenasa (DHODH), y es conocido por el tratamiento y la prevención de enfermedades, en particular su uso en enfermedades en las que existe una ventaja en la inhibición de la dihidroorotato deshidrogenasa (DHODH).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17203407 | 2017-11-23 | ||
PCT/EP2018/082272 WO2019101888A1 (en) | 2017-11-23 | 2018-11-22 | Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020005360A true MX2020005360A (es) | 2020-08-13 |
Family
ID=60452494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005360A MX2020005360A (es) | 2017-11-23 | 2018-11-22 | Compuestos y regimen de dosificacion para usarse en la prevencion o tratamiento de enfermedades inflamatorias cronicas y/o autoinmunes. |
Country Status (15)
Country | Link |
---|---|
US (3) | US20200360324A1 (es) |
EP (1) | EP3713554A1 (es) |
JP (2) | JP7231628B2 (es) |
KR (1) | KR20200090204A (es) |
CN (1) | CN111343975A (es) |
AU (1) | AU2018371177B2 (es) |
BR (1) | BR112020009477A2 (es) |
CA (1) | CA3083155A1 (es) |
IL (1) | IL274836A (es) |
MA (1) | MA50790A (es) |
MX (1) | MX2020005360A (es) |
PH (1) | PH12020550680A1 (es) |
SG (1) | SG11202002746YA (es) |
UA (1) | UA127354C2 (es) |
WO (1) | WO2019101888A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3892268B1 (en) * | 2020-04-10 | 2022-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of vidofludimus for the treatment of coronavirus infections |
CA3176008A1 (en) | 2020-04-21 | 2021-10-28 | Manfred Groppel | Vidofludimus for use in the treatment or prevention of viral diseases |
EP4313150A1 (en) | 2021-03-26 | 2024-02-07 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Pyrimidine biosynthesis inhibitor combination for use in treating viral infections |
CA3215002A1 (en) | 2021-04-09 | 2022-10-13 | Christian Gege | Deuterated dhodh inhibitors |
US11877994B2 (en) * | 2021-08-02 | 2024-01-23 | Immunic Ag | Treatment of multiple sclerosis comprising DHODH inhibitors |
TW202332433A (zh) | 2021-12-23 | 2023-08-16 | 德商埃慕尼克股份公司 | 含羧酸生物電子等排體之dhodh抑制劑 |
WO2023232884A1 (en) | 2022-06-01 | 2023-12-07 | Immunic Ag | Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof |
EP4389138A1 (en) | 2022-12-22 | 2024-06-26 | Cytoki Pharma ApS | Dosage regimen for interleukin-22 derivatives |
WO2024133936A2 (en) | 2022-12-22 | 2024-06-27 | Cytoki Pharma Aps | Dosage regimen for interleukin-22 derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04000224A (es) | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
TWI403506B (zh) * | 2008-06-16 | 2013-08-01 | Faes Farma Sa | 用於治療急性和慢性發炎疾病之5-(4-甲磺醯基-苯基)-噻唑衍生物類 |
UA108760C2 (uk) | 2010-07-01 | 2015-06-10 | Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби | |
EA201691057A1 (ru) | 2013-11-22 | 2016-10-31 | Джензим Корпорейшн | Новые способы лечения нейродегенеративных заболеваний |
-
2018
- 2018-11-22 UA UAA202003733A patent/UA127354C2/uk unknown
- 2018-11-22 WO PCT/EP2018/082272 patent/WO2019101888A1/en unknown
- 2018-11-22 KR KR1020207017605A patent/KR20200090204A/ko not_active Application Discontinuation
- 2018-11-22 CN CN201880073387.XA patent/CN111343975A/zh active Pending
- 2018-11-22 AU AU2018371177A patent/AU2018371177B2/en active Active
- 2018-11-22 JP JP2020527735A patent/JP7231628B2/ja active Active
- 2018-11-22 EP EP18803724.6A patent/EP3713554A1/en active Pending
- 2018-11-22 SG SG11202002746YA patent/SG11202002746YA/en unknown
- 2018-11-22 MA MA050790A patent/MA50790A/fr unknown
- 2018-11-22 US US16/766,531 patent/US20200360324A1/en not_active Abandoned
- 2018-11-22 MX MX2020005360A patent/MX2020005360A/es unknown
- 2018-11-22 CA CA3083155A patent/CA3083155A1/en active Pending
- 2018-11-22 BR BR112020009477-3A patent/BR112020009477A2/pt unknown
-
2020
- 2020-05-21 IL IL274836A patent/IL274836A/en unknown
- 2020-05-22 PH PH12020550680A patent/PH12020550680A1/en unknown
-
2022
- 2022-11-22 US US17/992,162 patent/US11877995B2/en active Active
-
2023
- 2023-02-16 JP JP2023022183A patent/JP2023057141A/ja active Pending
- 2023-12-06 US US18/531,121 patent/US20240100005A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11877995B2 (en) | 2024-01-23 |
RU2020120536A (ru) | 2021-12-23 |
CA3083155A1 (en) | 2019-05-31 |
AU2018371177A1 (en) | 2020-04-16 |
SG11202002746YA (en) | 2020-04-29 |
JP2023057141A (ja) | 2023-04-20 |
EP3713554A1 (en) | 2020-09-30 |
WO2019101888A1 (en) | 2019-05-31 |
CN111343975A (zh) | 2020-06-26 |
AU2018371177B2 (en) | 2023-10-19 |
US20240100005A1 (en) | 2024-03-28 |
US20230116729A1 (en) | 2023-04-13 |
UA127354C2 (uk) | 2023-07-26 |
IL274836A (en) | 2020-07-30 |
KR20200090204A (ko) | 2020-07-28 |
BR112020009477A2 (pt) | 2020-11-03 |
JP7231628B2 (ja) | 2023-03-01 |
RU2020120536A3 (es) | 2021-12-23 |
US20200360324A1 (en) | 2020-11-19 |
MA50790A (fr) | 2020-09-30 |
JP2021504313A (ja) | 2021-02-15 |
PH12020550680A1 (en) | 2021-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550680A1 (en) | Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases | |
EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
PH12014501718A1 (en) | Novel therapeutic agents | |
GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
PH12017501079A1 (en) | 1,3-thiazol-2-yl substituted benzamides | |
PH12019501802A1 (en) | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof | |
EA201990951A1 (ru) | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
EA201171361A1 (ru) | Ингибиторы внешнего медуллярного калиевого канала почек | |
BR112015022197A2 (pt) | tratamento de cataplexia | |
TR201901114T4 (tr) | Özgün immünomodülatör ve anti inflamatuvar bileşikler. | |
TN2019000281A1 (en) | Ferroportin-inhibitor salts | |
EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
MX2017016424A (es) | Compuestos para su uso en el tratamiento de trastornos neuromusculares. | |
MY196186A (en) | Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor | |
EA201290677A1 (ru) | Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения | |
PH12018501567A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
EA201790908A1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
EA201691402A1 (ru) | Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты | |
MX2017005282A (es) | Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik). | |
EA202091396A1 (ru) | Композиции и способы лечения метаболических состояний | |
MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
MX2023007476A (es) | Derivado de tetrahidroquinolina y uso medico del mismo. |